Lexicon Pharmaceuticals Inc (LXRX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Lonnel Coats
Employees:
90
8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS, TX 77381
2818633000

Lexicon Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the. treatment of neuropathic pain.

Data derived from most recent annual or quarterly report
Market Cap 426.52 Million Shares Outstanding188.726 Million Avg 30-day Volume 536.456 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.13
Price to Revenue2593.2818 Debt to Equity0.0 EBITDA-97.996 Million
Price to Book Value3.0776 Operating Margin-72489.2086 Enterprise Value222.109 Million
Current Ratio6.079 EPS Growth0 Quick Ratio5.972
1 Yr BETA 1.7756 52-week High/Low 3.48 / 1.31 Profit Margin-73341.0072
Operating Cash Flow Growth-2.1076 Altman Z-Score-9.6087 Free Cash Flow to Firm -73.295 Million
Earnings Report2023-05-04
View SEC Filings from LXRX instead.

View recent insider trading info

Lexicon Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding LXRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LXRX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-01 by Seth Kiernan
  • 4: filed on 2023-03-01 by McDermott Wendy
  • 4: filed on 2023-03-01 by MAIN ALAN J
  • 4: filed on 2023-03-01 by Kassler-Taub Kenneth B.
  • 4: filed on 2023-03-01 by GRANOWITZ CRAIG B
  • 4: filed on 2023-03-01 by CRUM BRIAN T
  • 4: filed on 2023-03-01 by WADE JEFFREY L
  • 4: filed on 2023-03-01 by COATS LONNEL
  • 4: filed on 2023-02-13 by ALEXANDER KRISTEN
  • 4: filed on 2023-02-13 by Seth Kiernan

    • Events (8k)

  • 8-K: filed on 2023-01-04:
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-30:
    Item 8.01: Other Events
  • 8-K: filed on 2022-05-25:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    563.6 Thousand total shares from 23 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WADE JEFFREY L PRESIDENT AND CFO

    • Officer
    		 242,341 2023-02-28 2

    MAIN ALAN J EVP, INNOV & CHEM SCIENCES

    • Officer
    		 212,586 2023-02-28 2

    COATS LONNEL CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 744,359 2023-02-28 2

    CRUM BRIAN T SVP, GENERAL COUNSEL & SECR.

    • Officer
    		 134,798 2023-02-28 2

    GRANOWITZ CRAIG B SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 15,185 2023-02-28 2

    ALEXANDER KRISTEN VP, FINANCE AND ACCOUNTING

    • Officer
    		 30,350 2023-02-28 2

    KASSLER-TAUB KENNETH B. SVP, REGULATORY & QA

    • Officer
    		 119,625 2023-02-28 2

    SETH KIERNAN VP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 53,136 2023-02-28 2

    MCDERMOTT WENDY VP, HUMAN RESOURCES

    • Officer
    		 12,478 2023-02-28 2

    INVUS US PARTNERS LLC

    ULYS, L.L.C.

    DEBBANE RAYMOND

    • Director
    • 10% Owner
    		 5,782,749 2022-08-05 5

    ARTAL INTERNATIONAL S.C.A.

    WITTOUCK AMAURY

    ARTAL INTERNATIONAL MANAGEMENT S.A.

    ARTAL GROUP S.A.

    WESTEND S.A.

    STICHTING ADMINISTRATIEKANTOOR WESTEND

    INVUS PUBLIC EQUITIES, L.P.

    INVUS, L.P.

    INVUS PUBLIC EQUITIES ADVISORS, LLC

    INVUS ADVISORS, L.L.C.

    • Director
    • 10% Owner
    		 86,262,020 2022-08-05 2

    DEBBANE RAYMOND

    • Director
    		 5,635,359 2022-08-01 5

    SOBECKI CHRISTOPHER J

    • Director
    		 23,704 2022-05-21 2

    LEFKOWITZ ROBERT J MD

    • Director
    		 23,704 2022-05-21 2

    BARKER SAM L

    • Director
    		 23,704 2022-05-21 2

    NIES ALAN S

    • Director
    		 23,704 2022-05-21 2

    PALANTONI FRANK

    • Director
    		 23,704 2022-05-21 2

    AMOUYAL PHILIPPE

    • Director
    		 23,704 2022-05-21 2

    SWAIN JUDITH L

    • Director
    		 23,704 2022-05-21 2

    TESSMER JAMES F VP, FINANCE & ACCOUNTING

    • Officer
    		 122,746 2021-03-15 0

    TYLE PRAVEEN EVP, R&D

    • Officer
    		 204,771 2021-02-28 0

    WITTOUCK AMAURY

    • Director
    • 10% Owner
    		 71,178,364 2021-01-11 0

    INVUS C.V.

    • Director
    • 10% Owner
    		 No longer subject to file 2020-12-31 0

    INVUS PARTNERS, LLC

    • Director
    • 10% Owner
    		 4,321,214 2020-12-31 0

    ARTAL INTERNATIONAL S.C.A.

    MINNE PASCAL

    ARTAL INTERNATIONAL MANAGEMENT S.A.

    ARTAL GROUP S.A.

    WESTEND S.A.

    STICHTING ADMINISTRATIEKANTOOR WESTEND

    • Director
    • 10% Owner
    		 71,178,364 2020-12-16 0

    INVUS PUBLIC EQUITIES, L.P.

    ARTAL TREASURY LTD

    INVUS, L.P.

    INVUS PUBLIC EQUITIES ADVISORS, LLC

    INVUS ADVISORS, L.L.C.

    • Director
    • 10% Owner
    		 71,178,364 2020-12-16 0

    LAPUERTA PABLO EVP AND CMO

    • Officer
    		 85,719 2020-04-22 0

    SANTINI ALEXANDER A EVP AND CCO

    • Officer
    		 55,584 2020-04-22 0

    INVUS PUBLIC EQUITIES, L.P.

    ARTAL INTERNATIONAL S.C.A.

    ARTAL INTERNATIONAL MANAGEMENT S.A.

    ARTAL GROUP S.A.

    WESTEND S.A.

    STICHTING ADMINISTRATIEKANTOOR WESTEND

    MINNE PASCAL

    INVUS, L.P.

    INVUS ADVISORS, L.L.C.

    INVUS PUBLIC EQUITIES ADVISORS, LLC

    • Director
    • 10% Owner
    		 3,516,214 2018-06-27 0

    NORTHCOTT JOHN VP, MARKETING, COMM STRATEGY

    • Officer
    		 8,235 2015-03-02 0

    INVUS C.V.

    ULYS, L.L.C.

    DEBBANE RAYMOND

    • Director
    • 10% Owner
    		 30,283,190 2014-12-12 0

    SANDS ARTHUR T PRESIDENT & CEO

    • Officer
    • Director
    		 1,898,829 2014-02-28 0

    ZAMBROWICZ BRIAN P EVP, CHIEF SCIENTIFIC OFFICER

    • Officer
    		 278,703 2014-02-28 0

    ULYS, LLC

    INVUS, L.P.

    INVUS PUBLIC EQUITIES, LP

    INVUS, CV

    INVUS ADVISORS, L.L.C.

    INVUS PUBLIC EQUITIES ADVISORS, LLC

    DEBBANE RAYMOND

    • Director
    • 10% Owner
    		 255,925,427 2011-12-22 5

    ULYS, LLC

    INVUS, L.P.

    INVUS ADVISORS, L.L.C.

    INVUS, CV

    DEBBANE RAYMOND

    • 10% Owner
    		 165,110,497 2010-03-19 5

    TRAGASH STEVEN ALAN VP, CORPORATE AFFAIRS

    • Officer
    		 0 2010-02-15 0

    BROWN PHILIP M SVP, CLINICAL DEVELOPMENT

    • Officer
    		 27,306 2010-02-12 0

    ULYS, LLC

    INVUS, L.P.

    INVUS ADVISORS, L.L.C.

    DEBBANE RAYMOND

    • 10% Owner
    		 66,949,183 2009-10-14 5

    BANSAL AJAY EVP CORP DEV AND CFO

    • Officer
    		 0 2009-06-02 0

    WILTSEY KATHLEEN M

    • Director
    		 0 2009-04-24 0

    HOWSON TAMAR D EVP OF BUS DEV

    • Officer
    		 0 2008-02-07 0

    ISHIMOTO LANCE K SVP, INTELLECTUAL PROPERTY

    • Officer
    		 0 2008-02-07 0

    PIGGOTT JAMES R PHD SVP OF PHARM BIO

    • Officer
    		 0 2008-02-07 0

    GREGORY JULIA P EVP AND CFO

    • Officer
    		 0 2008-02-07 0

    ROSE CLAYTON STUART

    • Director
    		 25,000 2007-06-26 0

    ULYS, LLC

    INVUS, L.P.

    INVUS ADVISORS, L.L.C.

    INVUS PUBLIC EQUITIES, LP

    INVUS PUBLIC EQUITIES ADVISORS, LLC

    DEBBANE RAYMOND

    • 10% Owner
    		 3,891,108 2007-06-17 0

    MILLS BARRY

    • Director
    		 25,000 2006-08-18 0

    COLBERT WALTER F SVP, HR AND CORP SERV

    • Officer
    		 30,000 2006-02-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    COATS LONNEL - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 16:46:57 -0500 2023-02-28 M 91,363 d 182,727 direct

    ALEXANDER KRISTEN - Officer VP, FINANCE AND ACCOUNTING

    		2023-03-01 16:56:29 -0500 2023-02-28 M 10,617 a 35,680 direct 22.9358 3.6697 22.9358 2 0.0 1

    ALEXANDER KRISTEN - Officer VP, FINANCE AND ACCOUNTING

    		2023-03-01 16:56:29 -0500 2023-02-28 M 5,400 d 0 direct

    ALEXANDER KRISTEN - Officer VP, FINANCE AND ACCOUNTING

    		2023-03-01 16:56:29 -0500 2023-02-28 M 5,400 a 22,363 direct 22.9358 3.6697 22.9358 2 0.0 1

    ALEXANDER KRISTEN - Officer VP, FINANCE AND ACCOUNTING

    		2023-03-01 16:56:29 -0500 2023-02-28 F 5,330 $2.17 d 30,350 direct 22.9358 3.6697 22.9358 2 0.0 1

    ALEXANDER KRISTEN - Officer VP, FINANCE AND ACCOUNTING

    		2023-03-01 16:56:29 -0500 2023-02-28 M 2,700 d 2,700 direct

    ALEXANDER KRISTEN - Officer VP, FINANCE AND ACCOUNTING

    		2023-03-01 16:56:29 -0500 2023-02-28 M 2,700 a 25,063 direct 22.9358 3.6697 22.9358 2 0.0 1

    GRANOWITZ CRAIG B - Officer SVP, CHIEF MEDICAL OFFICER

    		2023-03-01 16:50:54 -0500 2023-02-28 M 27,917 d 55,833 direct

    GRANOWITZ CRAIG B - Officer SVP, CHIEF MEDICAL OFFICER

    		2023-03-01 16:50:54 -0500 2023-02-28 M 27,917 a 27,917 direct 22.9358 3.6697 22.9358 2 0.0 1

    GRANOWITZ CRAIG B - Officer SVP, CHIEF MEDICAL OFFICER

    		2023-03-01 16:50:54 -0500 2023-02-28 F 12,732 $2.17 d 15,185 direct 22.9358 3.6697 22.9358 2 0.0 1

    ALEXANDER KRISTEN - Officer VP, FINANCE AND ACCOUNTING

    		2023-03-01 16:56:29 -0500 2023-02-28 M 10,617 d 21,233 direct

    COATS LONNEL - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 16:46:57 -0500 2023-02-28 M 91,363 a 795,330 direct 22.9358 3.6697 22.9358 2 0.0 1

    COATS LONNEL - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 16:46:57 -0500 2023-02-28 M 84,630 d 0 direct

    COATS LONNEL - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 16:46:57 -0500 2023-02-28 M 84,630 a 670,633 direct 22.9358 3.6697 22.9358 2 0.0 1

    COATS LONNEL - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 16:46:57 -0500 2023-02-28 F 50,971 $2.17 d 744,359 direct 22.9358 3.6697 22.9358 2 0.0 1

    COATS LONNEL - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 16:46:57 -0500 2023-02-28 M 33,334 d 33,333 direct

    COATS LONNEL - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 16:46:57 -0500 2023-02-28 M 33,334 a 703,967 direct 22.9358 3.6697 22.9358 2 0.0 1

    CRUM BRIAN T - Officer SVP, GENERAL COUNSEL & SECR.

    		2023-03-01 16:49:51 -0500 2023-02-28 M 26,097 d 52,193 direct

    CRUM BRIAN T - Officer SVP, GENERAL COUNSEL & SECR.

    		2023-03-01 16:49:51 -0500 2023-02-28 M 26,097 a 155,335 direct 22.9358 3.6697 22.9358 2 0.0 1

    MCDERMOTT WENDY - Officer VP, HUMAN RESOURCES

    		2023-03-01 16:54:25 -0500 2023-02-28 M 18,943 a 18,943 direct 22.9358 3.6697 22.9358 2 0.0 1

    WADE JEFFREY L - Officer PRESIDENT AND CFO

    		2023-03-01 16:48:08 -0500 2023-02-28 M 37,273 d 74,547 direct

    WADE JEFFREY L - Officer PRESIDENT AND CFO

    		2023-03-01 16:48:08 -0500 2023-02-28 M 37,273 a 272,596 direct 22.9358 3.6697 22.9358 2 0.0 1

    WADE JEFFREY L - Officer PRESIDENT AND CFO

    		2023-03-01 16:48:08 -0500 2023-02-28 M 30,467 d 0 direct

    WADE JEFFREY L - Officer PRESIDENT AND CFO

    		2023-03-01 16:48:08 -0500 2023-02-28 M 30,467 a 224,147 direct 22.9358 3.6697 22.9358 2 0.0 1

    WADE JEFFREY L - Officer PRESIDENT AND CFO

    		2023-03-01 16:48:08 -0500 2023-02-28 F 30,255 $2.17 d 242,341 direct 22.9358 3.6697 22.9358 2 0.0 1

    WADE JEFFREY L - Officer PRESIDENT AND CFO

    		2023-03-01 16:48:08 -0500 2023-02-28 M 11,176 d 11,177 direct

    WADE JEFFREY L - Officer PRESIDENT AND CFO

    		2023-03-01 16:48:08 -0500 2023-02-28 M 11,176 a 235,323 direct 22.9358 3.6697 22.9358 2 0.0 1

    MCDERMOTT WENDY - Officer VP, HUMAN RESOURCES

    		2023-03-01 16:54:25 -0500 2023-02-28 M 18,943 d 37,887 direct

    CRUM BRIAN T - Officer SVP, GENERAL COUNSEL & SECR.

    		2023-03-01 16:49:51 -0500 2023-02-28 M 21,030 d 0 direct

    MCDERMOTT WENDY - Officer VP, HUMAN RESOURCES

    		2023-03-01 16:54:25 -0500 2023-02-28 F 6,465 $2.17 d 12,478 direct 22.9358 3.6697 22.9358 2 0.0 1

    SETH KIERNAN - Officer VP, CHIEF COMMERCIAL OFFICER

    		2023-03-01 16:55:29 -0500 2023-02-28 M 22,963 d 45,927 direct

    SETH KIERNAN - Officer VP, CHIEF COMMERCIAL OFFICER

    		2023-03-01 16:55:29 -0500 2023-02-28 M 22,963 a 64,949 direct 22.9358 3.6697 22.9358 2 0.0 1

    SETH KIERNAN - Officer VP, CHIEF COMMERCIAL OFFICER

    		2023-03-01 16:55:29 -0500 2023-02-28 M 14,833 d 0 direct

    SETH KIERNAN - Officer VP, CHIEF COMMERCIAL OFFICER

    		2023-03-01 16:55:29 -0500 2023-02-28 M 14,833 a 36,700 direct 22.9358 3.6697 22.9358 2 0.0 1

    SETH KIERNAN - Officer VP, CHIEF COMMERCIAL OFFICER

    		2023-03-01 16:55:29 -0500 2023-02-28 F 11,813 $2.17 d 53,136 direct 22.9358 3.6697 22.9358 2 0.0 1

    SETH KIERNAN - Officer VP, CHIEF COMMERCIAL OFFICER

    		2023-03-01 16:55:29 -0500 2023-02-28 M 5,286 d 5,287 direct

    SETH KIERNAN - Officer VP, CHIEF COMMERCIAL OFFICER

    		2023-03-01 16:55:29 -0500 2023-02-28 M 5,286 a 41,986 direct 22.9358 3.6697 22.9358 2 0.0 1

    CRUM BRIAN T - Officer SVP, GENERAL COUNSEL & SECR.

    		2023-03-01 16:49:51 -0500 2023-02-28 M 21,030 a 120,488 direct 22.9358 3.6697 22.9358 2 0.0 1

    MAIN ALAN J - Officer EVP, INNOV & CHEM SCIENCES

    		2023-03-01 16:53:02 -0500 2023-02-28 M 8,976 a 207,865 direct 22.9358 3.6697 22.9358 2 0.0 1

    MAIN ALAN J - Officer EVP, INNOV & CHEM SCIENCES

    		2023-03-01 16:53:02 -0500 2023-02-28 M 8,976 d 8,977 direct

    MAIN ALAN J - Officer EVP, INNOV & CHEM SCIENCES

    		2023-03-01 16:53:02 -0500 2023-02-28 F 20,946 $2.17 d 212,586 direct 22.9358 3.6697 22.9358 2 0.0 1

    MAIN ALAN J - Officer EVP, INNOV & CHEM SCIENCES

    		2023-03-01 16:53:02 -0500 2023-02-28 M 23,300 a 198,889 direct 22.9358 3.6697 22.9358 2 0.0 1

    MAIN ALAN J - Officer EVP, INNOV & CHEM SCIENCES

    		2023-03-01 16:53:02 -0500 2023-02-28 M 23,300 d 0 direct

    MAIN ALAN J - Officer EVP, INNOV & CHEM SCIENCES

    		2023-03-01 16:53:02 -0500 2023-02-28 M 25,667 a 233,532 direct 22.9358 3.6697 22.9358 2 0.0 1

    MAIN ALAN J - Officer EVP, INNOV & CHEM SCIENCES

    		2023-03-01 16:53:02 -0500 2023-02-28 M 25,667 d 51,333 direct

    KASSLER-TAUB KENNETH B. - Officer SVP, REGULATORY & QA

    		2023-03-01 16:51:47 -0500 2023-02-28 M 7,086 a 111,186 direct 22.9358 3.6697 22.9358 2 0.0 1

    KASSLER-TAUB KENNETH B. - Officer SVP, REGULATORY & QA

    		2023-03-01 16:51:47 -0500 2023-02-28 M 7,086 d 7,087 direct

    KASSLER-TAUB KENNETH B. - Officer SVP, REGULATORY & QA

    		2023-03-01 16:51:47 -0500 2023-02-28 M 18,243 d 0 direct

    KASSLER-TAUB KENNETH B. - Officer SVP, REGULATORY & QA

    		2023-03-01 16:51:47 -0500 2023-02-28 M 18,243 a 104,100 direct 22.9358 3.6697 22.9358 2 0.0 1

    CRUM BRIAN T - Officer SVP, GENERAL COUNSEL & SECR.

    		2023-03-01 16:49:51 -0500 2023-02-28 F 20,537 $2.17 d 134,798 direct 22.9358 3.6697 22.9358 2 0.0 1

    CRUM BRIAN T - Officer SVP, GENERAL COUNSEL & SECR.

    		2023-03-01 16:49:51 -0500 2023-02-28 M 8,750 d 8,750 direct

    CRUM BRIAN T - Officer SVP, GENERAL COUNSEL & SECR.

    		2023-03-01 16:49:51 -0500 2023-02-28 M 8,750 a 129,238 direct 22.9358 3.6697 22.9358 2 0.0 1

    KASSLER-TAUB KENNETH B. - Officer SVP, REGULATORY & QA

    		2023-03-01 16:51:47 -0500 2023-02-28 M 27,557 d 55,113 direct

    KASSLER-TAUB KENNETH B. - Officer SVP, REGULATORY & QA

    		2023-03-01 16:51:47 -0500 2023-02-28 M 27,557 a 138,743 direct 22.9358 3.6697 22.9358 2 0.0 1

    KASSLER-TAUB KENNETH B. - Officer SVP, REGULATORY & QA

    		2023-03-01 16:51:47 -0500 2023-02-28 F 19,118 $2.17 d 119,625 direct 22.9358 3.6697 22.9358 2 0.0 1

    WADE JEFFREY L - Officer PRESIDENT AND CFO

    		2023-02-13 16:56:55 -0500 2023-02-09 A 442,030 a 442,030 direct

    ALEXANDER KRISTEN - Officer VP, FINANCE AND ACCOUNTING

    		2023-02-13 17:06:53 -0500 2023-02-09 A 47,780 a 47,780 direct

    ALEXANDER KRISTEN - Officer VP, FINANCE AND ACCOUNTING

    		2023-02-13 17:06:53 -0500 2023-02-09 A 71,670 a 71,670 direct

    SETH KIERNAN - Officer VP, CHIEF COMMERCIAL OFFICER

    		2023-02-13 17:04:25 -0500 2023-02-09 A 93,370 a 93,370 direct

    SETH KIERNAN - Officer VP, CHIEF COMMERCIAL OFFICER

    		2023-02-13 17:04:25 -0500 2023-02-09 A 280,100 a 280,100 direct

    MCDERMOTT WENDY - Officer VP, HUMAN RESOURCES

    		2023-02-13 17:02:37 -0500 2023-02-09 A 83,090 a 83,090 direct

    MCDERMOTT WENDY - Officer VP, HUMAN RESOURCES

    		2023-02-13 17:02:37 -0500 2023-02-09 A 249,280 a 249,280 direct

    MAIN ALAN J - Officer EVP, INNOV & CHEM SCIENCES

    		2023-02-13 17:01:21 -0500 2023-02-09 A 98,710 a 98,710 direct

    MAIN ALAN J - Officer EVP, INNOV & CHEM SCIENCES

    		2023-02-13 17:01:21 -0500 2023-02-09 A 296,130 a 296,130 direct

    KASSLER-TAUB KENNETH B. - Officer SVP, REGULATORY & QA

    		2023-02-13 17:00:06 -0500 2023-02-09 A 98,270 a 98,270 direct

    KASSLER-TAUB KENNETH B. - Officer SVP, REGULATORY & QA

    		2023-02-13 17:00:06 -0500 2023-02-09 A 294,810 a 294,810 direct

    GRANOWITZ CRAIG B - Officer SVP, CHIEF MEDICAL OFFICER

    		2023-02-13 16:59:05 -0500 2023-02-09 A 107,370 a 107,370 direct

    GRANOWITZ CRAIG B - Officer SVP, CHIEF MEDICAL OFFICER

    		2023-02-13 16:59:05 -0500 2023-02-09 A 322,110 a 322,110 direct

    COATS LONNEL - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-13 16:55:58 -0500 2023-02-09 A 361,150 a 361,150 direct

    COATS LONNEL - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-13 16:55:58 -0500 2023-02-09 A 1,083,440 a 1,083,440 direct

    CRUM BRIAN T - Officer SVP, GENERAL COUNSEL & SECR.

    		2023-02-13 16:58:03 -0500 2023-02-09 A 100,370 a 100,370 direct

    CRUM BRIAN T - Officer SVP, GENERAL COUNSEL & SECR.

    		2023-02-13 16:58:03 -0500 2023-02-09 A 301,100 a 301,100 direct

    WADE JEFFREY L - Officer PRESIDENT AND CFO

    		2023-02-13 16:56:55 -0500 2023-02-09 A 147,340 a 147,340 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-24 15:45:03 UTC 4.179 0.641 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-24 15:15:03 UTC 4.179 0.641 1100000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-24 14:45:03 UTC 4.179 0.641 1100000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-24 14:15:03 UTC 4.179 0.641 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-24 13:45:03 UTC 3.134 1.436 1800000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-24 13:15:04 UTC 3.134 1.436 1800000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-24 12:45:03 UTC 3.134 1.436 1800000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 22:15:04 UTC 3.134 1.436 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 21:45:04 UTC 3.134 1.436 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 21:15:04 UTC 3.134 1.436 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 20:45:03 UTC 3.134 1.436 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 20:15:03 UTC 3.134 1.436 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 19:45:03 UTC 3.134 1.436 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 19:15:03 UTC 3.134 1.436 1100000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 18:45:04 UTC 3.134 1.436 1100000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 18:15:03 UTC 3.134 1.436 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 17:45:03 UTC 3.134 1.436 1000000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 17:15:03 UTC 3.134 1.436 1100000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 16:45:04 UTC 3.134 1.436 1100000
    LEXICON PHARMACEUTICALS INC LXRX 2023-03-23 16:15:03 UTC 3.134 1.436 1100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund LXRX -3400.0 shares, $-6494.0 2022-12-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments